Imaging suggests tirzepatide boosts brown fat to aid weight loss

In a 24-week trial, tirzepatide significantly increased brown adipose tissue activity and volume on PET/CT and MRI compared with placebo (about 65% vs 41%), suggesting the GLP-1 drug may boost energy expenditure and promote white-to-beige fat conversion, contributing to weight loss beyond appetite suppression.